



Ref. No.: WOCK/SEC/SE/2024-25/076

13<sup>th</sup> November, 2024

<b>BSE Limited</b> Corporate Relations Department P J Towers, Dalal Street <b>Mumbai - 400 001</b>  <b><u>Scrip Code: 532300</u></b>	<b>National Stock Exchange of India Limited</b> Exchange Plaza Bandra Kurla Complex, Bandra (E), <b>Mumbai - 400 051</b>  <b><u>NSE Symbol: WOCKPHARMA</u></b>
---	---

**Sub: Statement on Deviation or Variation of funds raised through Qualified Institutions Placement for the quarter ended 30<sup>th</sup> September, 2024**

Dear Sir/Madam,

Pursuant to Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, we hereby confirm that there has been no deviation in the utilization of Issue proceeds from the objects as stated in the Placement Document dated 26<sup>th</sup> March 2024 for Qualified Institutions Placement ("QIP").

The 'Statement of deviation' in the prescribed format, confirming Nil deviation, duly reviewed by the Audit Committee is attached herewith as '**Annexure A**'.

Kindly take the above information on record.

Thanking you,

For **Wockhardt Limited**

**Rashmi Mamtura**  
**Company Secretary**

Encls: A/a.

**Annexure A**

**Statement of Deviation / Variation for proceeds of Qualified Institutions Placement**

<b>Name of the Company</b>	Wockhardt Limited
<b>Mode of Fund Raising</b>	Qualified Institutions Placement
<b>Date of Raising Funds</b>	26-03-2024
<b>Amount Raised (in Rs. Crores)</b>	480.04
<b>Report filed for Quarter ended</b>	30-09-2024
<b>Monitoring Agency</b>	Applicable
<b>Monitoring Agency Name, if applicable</b>	CRISIL RATINGS LIMITED
<b>Is there a Deviation / Variation in use of funds raised</b>	No
<b>If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders</b>	Not Applicable
<b>If Yes, Date of shareholder Approval</b>	Not Applicable
<b>Explanation for the Deviation / Variation</b>	Not Applicable
<b>Comments of the Audit Committee after review</b>	No Deviation
<b>Comments of the auditors, if any</b>	Not Applicable

**Objects for which funds have been raised and where there has been a deviation, in the following table.**

<b>Original Object</b>	<b>Modified Object, if any</b>	<b>Original Allocation (Rs. in crore)</b>	<b>Modified allocation, if any</b>	<b>Funds Utilised (Rs. in crore)</b>	<b>Amount of Deviation/ Variation for the quarter according to applicable object</b>	<b>Remarks if any</b>
Repayment and / or pre – payment, in full or part, of certain borrowings availed by our Company	No	110.00	Nil	109.41	Nil	N.A.
Funding of costs related to the clinical trials and research and development undertaken by the Company and/ or Wockhardt Bio AG, one of the Subsidiaries of the Company	No	210.00	Nil	141.68	Nil	N.A.
Funding working capital requirements of the Company	No	115.00	Nil	114.95	Nil	N.A.

General corporate purposes	No	27.87	Nil	27.81	Nil	N.A.
<b>Total Net Proceeds*</b>		<b>462.87</b>		<b>393.85</b>		

\*Excluding estimated 'Issue related expenses'.

**For Wockhardt Ltd**

**Rashmi Mamtura**  
**Company Secretary & Compliance Officer**